Back to Menu
Basis for Glioma Diagnosis
1.Clinical presentation and neurological examination A detailed history is obtained, and consciousness, language, motor function, and coordination are evaluated to preliminarily localize the lesion.
2.Computed tomography (CT) Used for emergency screening to rapidly detect mass effect, hemorrhage, and edema, but it is less sensitive for low-grade tumors.
3.Magnetic resonance imaging (MRI), non-contrast and contrast-enhanced The core first-line imaging approach: non-contrast sequences localize the lesion, and contrast enhancement reflects malignancy and blood–brain barrier disruption.
4.Multimodal MRI MRS, PWI, and DTI assess metabolism, perfusion, and white matter tracts, supporting precise evaluation and biopsy planning.
5.Positron emission tomography (PET-CT) Assesses metabolic activity, helps distinguish recurrence from radiation necrosis, and is used for staging and response assessment.
6.Pathological diagnosis Microscopic evaluation of stereotactic biopsy or surgical specimens is the gold standard for determining subtype and WHO grade.
7.Molecular pathology testing Testing markers such as IDH, 1p/19q, MGMT, and TERT guides classification, prognostic stratification, and targeted treatment selection.
8.Other adjunctive methods EEG is used to assess seizures; CSF testing is used in selected settings or to evaluate dissemination, and is not routine.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that delayed diagnosis of glioma can have serious consequences. Vigilance for neurological warning signs and early diagnosis through MRI, pathology, and molecular testing are essential to secure the therapeutic window and preserve function. Accurate diagnosis is the fundamental prerequisite for individualized multimodal treatment and improved outcomes.
Basis for Glioma Diagnosis
1.Clinical presentation and neurological examination A detailed history is obtained, and consciousness, language, motor function, and coordination are evaluated to preliminarily localize the lesion.
2.Computed tomography (CT) Used for emergency screening to rapidly detect mass effect, hemorrhage, and edema, but it is less sensitive for low-grade tumors.
3.Magnetic resonance imaging (MRI), non-contrast and contrast-enhanced The core first-line imaging approach: non-contrast sequences localize the lesion, and contrast enhancement reflects malignancy and blood–brain barrier disruption.
4.Multimodal MRI MRS, PWI, and DTI assess metabolism, perfusion, and white matter tracts, supporting precise evaluation and biopsy planning.
5.Positron emission tomography (PET-CT) Assesses metabolic activity, helps distinguish recurrence from radiation necrosis, and is used for staging and response assessment.
6.Pathological diagnosis Microscopic evaluation of stereotactic biopsy or surgical specimens is the gold standard for determining subtype and WHO grade.
7.Molecular pathology testing Testing markers such as IDH, 1p/19q, MGMT, and TERT guides classification, prognostic stratification, and targeted treatment selection.
8.Other adjunctive methods EEG is used to assess seizures; CSF testing is used in selected settings or to evaluate dissemination, and is not routine.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that delayed diagnosis of glioma can have serious consequences. Vigilance for neurological warning signs and early diagnosis through MRI, pathology, and molecular testing are essential to secure the therapeutic window and preserve function. Accurate diagnosis is the fundamental prerequisite for individualized multimodal treatment and improved outcomes.